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Background: The redox-active pyocyanin (PCN) is a toxic, secondary metabolite secreted by the respiratory
pathogen Pseudomonas aeruginosa (PA). Previously, we have shown that mouse lungs chronically exposed to PCN
develop goblet cell hyperplasia and metaplasia (GCHM) and mucus hypersecretion, fibrosis and emphysema. These
pathological features are commonly found in the airways of several chronic lung diseases, including cystic fibrosis
(CF), as well as in mouse airways deficient in the forkhead box A2 (FOXA2), a transcriptional repressor of goblet
GCHM and mucus biosynthesis. Furthermore, PCN inhibits FOXA2 by activating the pro-GCHM signaling pathways
Stat6 and EGFR. However, it is not known whether PCN-generated reactive oxygen (ROS) and nitrogen (RNS)
species posttranslationally modify and inactivate FOXA2.
Methods: We examined the posttranslational modifications of FOXA2 by PCN using specific antibodies against
oxidation, nitrosylation, acetylation and ubiquitination. Electrophoretic mobility shift assay (EMSA) was used to
examine the ability of modified FOXA2 to bind the promoter of MUC5B mucin gene. In addition, we used
quantitative real time PCR, ELISA, immunofluorescence and mouse lung infection to assess whether the loss of
FOXA2 function caused GCHM and mucin overexpression. Finally, we examined the restoration of FOXA2 function
by the antioxidant glutathione (GSH).
Results: We found that PCN-generated ROS/RNS caused nitrosylation, acetylation, ubiquitination and degradation
of FOXA2. Modified FOXA2 had reduced ability to bind the promoter of the MUC5B gene. The antioxidant GSH
alleviated the modification of FOXA2 by PCN, and inhibited the overexpression of MUC5AC and MUC5B mucins.
Conclusion: These results suggest that PCN-mediated posttranslational modifications of FOXA2 are positively
correlated with GCHM and overexpression of airway mucins. Furthermore, antioxidant treatment restores the
function of FOXA2 to attenuate GCHM and mucus hypersecretion.
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Mucus hypersecretionBackground
Pseudomonas aeruginosa (PA) is an important pathogen
of patients with cystic fibrosis (CF) and non-CF bron-
chiectasis, and chronic obstructive pulmonary disease
(COPD) [1-3]. PA infection is associated with more
sputum, extensive bronchiectasis, increased hospitali-
zations and worse quality of life. PA elaborates mul-
tiple virulence factors to thrive in the mucus-rich
airways [4]. However, at chronic stage, PA alters its* Correspondence: geelau@illinois.edu
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reproduction in any medium, provided the orvirulence [4,5], by repressing the expression of flagella
[6], mutating the immunogenic O-antigen of LPS [7],
overproducing the mucoid alginate [8] and switching
to the biofilm mode of growth [9]. However, alginate
is poorly immunogenic [10]. PA factors that are still
secreted abundantly include the quorum-sensing ef-
fectors homoserine lactones and quinolones, which
regulate biofilm formation [4,5]. However, at approxi-
mately 20 nM concentration found within CF airways,
these effectors are thought to be non-toxic [4]. An-
other important PA factor is the redox-active exotoxin
pyocyanin (PCN) [4,11]. A previous study involving lim-
ited sputum samples from CF and non-CF bronchiectatic. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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spectively [12]. Importantly, PA increases PCN pro-
duction when cultured in medium supplemented with
CF sputum [13].
PCN redox cycles and forms ROS [11]. PCN-generated
O2
- can react with NO to form RNS, including the highly
toxic peroxynitrite. ROS/RNS damage host targets (DNA,
lipid, proteins) and modulate cellular and inflammatory
functions [14]. PCN depletes GSH in cultured airway
epithelial cells [15] and inactivates catalase [16]. Excessive
ROS/RNS production and inhibition of antioxidative
mechanisms by PCN overwhelm the antioxidant capacity
of the tissue, leading to lung damage. PCN damages cili-
ated epithelium and inhibits mucus transport [12], induces
bronchoconstriction [17], and decreases trachea mucus
velocity [18,19]. Furthermore, PCN inhibits NO produc-
tion in macrophages and endothelial cells [20], prostacyc-
lin production by endothelial cells [21], oxidation of
leukotriene B4 by neutrophils [22], eicosanoid metabolism
by platelets [23], and production of IL-2 and the IL-2
receptor in T cells [24]. PCN has opposite effects on air-
way epithelial cells, inhibiting the release of RANTES and
MCP-1 while stimulating Ca2+ signaling and IL-8 release
[25,26]. Finally, PCN inactivates α1-protease inhibitor [27]
and causes apoptosis in neutrophils [28]. Antioxidants
detoxify PCN, suggesting that its virulence is redox
dependent [22,26,28,29].
Importantly, we have shown that PCN is important for
both acute and chronic lung infections [30,31]. GCHM,
excessive mucus secretion and defective mucociliary
clearance, airway obstruction, bacterial infection, and
neutrophilic infiltration are important clinical features of
CF and other chronic airway diseases [1-3]. We have
shown that mouse lungs chronically exposed to PCN
undergo remodeling characterized by over-proliferation
of goblet cells in large bronchi and terminal bronchioles,
emphysema, fibrosis, and an influx of immune cells [31].
These pathological features resemble the airways of
FOXA2−/− mice [32], as well as the CF and COPD airways
chronically infected by PA. Importantly, we have shown
that PCN inhibits FOXA2 expression by activating the
pro-GCHM signaling pathways Stat6 and EGFR [31,33]. In
this study, we tested the hypothesis that PCN-generated
ROS/RNS posttranslationally modify FOXA2, disabling its
ability to regulate GCHM and mucin expression.Materials and methods
PCN and chemicals
All chemicals, including PCN were purchased from
Sigma Chemical Co., unless stated otherwise. Chemically
synthesized PCN (Sigma, #R9532) (St. Louis, MO, USA)
is preferred over PCN purified from PA cultures to
eliminate any contaminants (e.g., LPS, CpG DNA),which may cause lung injuries. PCN was resuspended
to 1 μg/ml in sterile H2O.
Cell cultures
The human lung mucoepidermoid carcinoma cell line
NCI-H292 was purchased from the American Type Culture
Collection (ATCC) (Manassas, VA, USA). 16HBE cells [1]
were a generous gift from Dr. D.C. Gruenert (University of
California, San Francisco, CA). NCI-H292 and 16HBE cells
were cultured in RPMI-1640 and MEM respectively,
supplemented with 10% fetal bovine serum in 5% CO2.
Epithelial cells that reached 70% confluency were serum-
starved for 24 hr before exposure to indicated concentra-
tions of PCN. As a control, cells were exposed to sterile
H2O that corresponded to maximum volume of PCN used
in each experiment. For example, 12.5 μl/ml sterile water
was used per milliliter of culture medium in Figure 1B.
Normal human bronchial epithelial (NHBE) cells were pur-
chased from Lonza (Walkersville, MD, USA). Cells were
passaged in 5% CO2 at 37°C using the bronchial epithelial
growth medium (BEGM) supplemented with growth fac-
tors supplied in the SingleQuot® kit (Lonza). NHBE cells at
passages 2 to 4, and 16HBE cells were trypsinized and
seeded onto the Costar Transwells® inserts with 0.4 μm
pore size (Corning) (Tewksbury, MA, USA) at a density of
1.5 × 105 cells/cm2 in media comprised of 50% BEBM and
50% DMEM-F12 low glucose (Invitrogen, Grand Island,
NY, USA) supplemented with the growth factors provided
in the SingleQuot® kits and retinoic acid (50 nM). Once the
cells reached confluency (approximately seven days after
seeding), they were switched to an air-liquid interface for
an additional 2 weeks to achieve mucociliary differentiation.
PCN (12.5 μg/ml) or IL-13 (1 μg/ml) was added to the
Transwell chambers for 24 hr. Sterile water was used as the
control. NHBE cells were stained with mouse anti-
MUC5AC monoclonal antibody (clone 45 M1, Santa Cruz
Biotechnology, Santa Cruz, CA, USA, #sc-21701, dilution
1:500), and visualized with Alexa Fluor®488-conjugated sec-
ondary antibodies (green color) under a confocal micro-
scope. Nuclei were stained with DAPI (blue color).
Brightfield and fluorescence images of these cells can be
found in the Additional file 1: Figure S1 and Additional
file 2: Figure S2.
ROS assays
ROS levels in PCN-exposed NCI-H292 cells were deter-
mined using the OxiSelect™ In Vitro ROS/RNS Assay
Kit according to the manufacturer protocols (#STA-347,
Cell Biolabs, San Diego, CA, USA). The assay uses the spe-
cific ROS/RNS probe dichlorodihydrofluorescin DiOxyQ
(DCFH-DiOxyQ). The DCFH-DiOxyQ probe is first
primed with a quench removal reagent, and subsequently
stabilized in the highly reactive DCFH form. ROS and RNS
species react with DCFH, which then rapidly oxidizes to
Figure 1 PCN causes oxidative stress in NCI-H292 cells.
(A) PCN is redox active, and induces the formation of ROS and RNS.
(B) NCI-H292 cells were exposed to PCN at indicated concentrations
in the presence or absence of GSH for 24 hr. For antioxidant
treatment, NCI-H292 cells were prexposed to GSH for 60 min before
PCN was added. The experiments were performed in triplicates for
three times with similar results. The mean ± standard deviation (SD)
from one typical experiment is shown. *p < 0.05 when comparing
PCN-exposed cells against control cells exposed to 12.5 μl sterile
water per milliliter of culture medium.
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(DCF). Fluorescence intensity is proportional to the total
ROS/RNS levels within the sample. The DCFH-DiOxyQ
probe can react with hydrogen peroxide (H2O2), peroxyl
radical (ROO·), nitric oxide (NO), and peroxynitrite anion
(ONOO-), allowing for measurement of the total free rad-
ical population within a sample.
Mucin analysis
NCI-H292 or 16HBE cells were stimulated with indicated
concentrations of PCN for 24 hr. Cells were lysed by the
M-PER Mammalian Protein Extraction Reagent (#78501,
Thermo Scientific, Rockford, IL, USA) in the presence
of the Halt Protease Inhibitor Cocktail (Thermo Scientific #
87786). The protease inhibitors were incorporated because
of prior reports of sensitivity of the anti-mucin antibodiesto degradation with cell lysates [34,35]. The amounts
of mucins in total cell lysates were determined by west-
ern blotting using specific antibodies against MUC5AC
(Santa Cruz Biotechnology #sc-21701, dilution 1:1000)
and MUC5B (Santa Cruz Biotechnology #sc-20119, di-
lution 1:1000) or by ELISA kits (USCN LIFE SCIENCE,
Houston, TX, USA, MUC5AC #E90756Hu; MUC5B #
E90684Hu). These ELISA kits have been previously used
in mucin studies [36-38].
Posttranslational modification of FOXA2
Nuclear proteins from PCN-stimulated or control NCI-
H292 cells were purified using the NE-PER Nuclear
and Cytoplasmic Extraction Reagents (Thermo Scientific #
78835). FOXA2 was immunoprecipitated using anti-
FOXA2 antibody (Santa Cruz Biotechnology #sc-101060)
immobilized on Protein A/G Agarose (Thermo Scientific #
89931). Posttranslational modifications of FOXA2 were
analyzed by western blot using antibodies against nitro-
tyrosine (Santa Cruz Biotechnology #sc-101358, dilution
1:1000), acetylated lysine (Abcam Cambridge, MA USA, #
ab80178, dilution 1:1000), methylated lysine (Abcam, #
ab76118), and ubiquitin (Santa Cruz Biotechnology, #FL-
76, dilution 1:1000).
Neutralization of PCN by GSH
NCI-H292 cells were pretreated with GSH at indicated
concentrations (0.2 to 10 mM) for 60 min before expos-
ure to PCN or sterile H2O for 24 hr. Total or nuclear
proteins were extracted for western blotting or ELISA.
The levels of GSH in rodent lungs have been measured
to be 2 mM [39]. GSH at concentrations as high as
10 mM has been used in cell cultures [40].
Western blot analyses
Cytoplasmic or nuclear proteins were separated by 8%
SDS-PAGE and transferred to PVDF membrane (Bio-Rad,
Hercules, CA, USA, #162-0177). Membranes were probed
with individual primary antibodies. The immune complexes
were visualized by the HRP-conjugated anti-mouse or anti-
rabbit secondary antibodies (1:5000 dilution) using the
ECL Western Blotting Detection System (Amersham
Biosciences, Piscataway, NJ, USA #RPN2132) on Kodak
BioMax X-ray films (Kodak, Rochester, NY, USA, #Kodak
XAR-51651454). The membranes were stripped and probed
with anti-β-actin antibody (Santa Cruz Biotechnology #
47778, dilution 1:2000) as loading control for MUC5AC
and MUC5B or with anti-H3 antibody (Santa Cruz
Biotechnology #sc-8655, dilution 1:2000) as control for
FOXA2.
EMSA
Nuclear extracts from PCN-treated and control NCI-
H292 cells were immunoprecipitated with anti-FOXA2
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(Thermo Scientific #26147). Immunoprecipitated FOXA2
free of antibody contamination (2.5 μg) was incubated with
the biotin-labeled probes in incubation buffer (10 mM
Hepes pH 7.9, 1 mM EDTA, 5 mM MgCl2, 10% glycerol,
0.5 m MDTT, 1 mg/ml BSA and 1 μg PolydI · dC) for
20 min at room temperature. The biotin-labeled probes
used were: Forward 5′-CCTCCCCGAGAGCAAACAC
ACGTGGCTGGA-3′, and Reverse: 5′-TCCAGCCACGT
GTGTTTGCTCTCGGGGAGG-3′, corresponding to the
FOXA2 binding site on MUC5B gene promoter. For
competition assays, extracts were incubated with 20-fold
excess of unlabeled probes or with anti-FOXA2 antibody.
FOXA2-DNA complexes were separated on a 6% acryl-
amide gel, transferred to Hybond nitrocellulose membranes
(Amersham Biosciences #RPN2020D), and developed using
the LightShift Chemiluminescent EMSA Kit (Thermo
Scientific #20148).
Quantitative real-time polymerase chain reaction
(qRT-PCR) analysis
NCI-H292 cells were cultured in 6-well plates and stim-
ulated with 0, 3.125, or 12.5 μg/ml of PCN for 24 hr
with or without pretreatments with 0.4, 1.0, or 2.5 mM
concentrations of GSH for 60 min before exposure to
PCN. Total RNA was extracted using the RNeasy Mini
Kit (Qiagen # 74104) according to the manufacturer’s
instructions. Equal amount of total RNA (3 μg) was re-
verse transcribed into cDNA using oligo(dT) primers
and SuperScript III reverse transcriptase (Invitrogen).
After the reverse transcription reaction, the first-stranded
cDNA was then diluted and used in each subsequent PCR
reaction. The qRT-PCR were performed on a 7900 HT
real-time PCR system by using 10 μl of cDNA in the pres-
ence of Taqman primers predesigned by Applied Biosys-
tems (Grand Island, New York) based on the sequence of
the target genes, according to the manufacturer’s protocol.
The relative expression of each gene was normalized to
GAPDH to give a relative expression level. The primers
information of MUC5AC, MUC5B and GAPDH genes
are propriety information belonging to the Applied Bio-
systems. The Assay IDs for these primers are: MUC5AC:
Hs01370716_m1, MUC5B: Hs 00861588_m1 and GAPDH:
Hs 99999905_m1.
Mouse lung infection and histopathological evaluation
C57BL6 mice (6-week old, Harlan Sprague Dawley,
Indianapolis, IN, USA) were housed in positively-ventilated
microisolator cages with automatic recirculating water,
located in a room with laminar, high efficiency particle ac-
cumulation–filtered air. The animals received autoclaved
food, water, and bedding. Mice (8/group) were anesthetized
with isoflurane, and intranasally-infected with 1 × 106 wild-
type PA strain PAO1 or isogenic ΔphzS bacteria [30] onDay 1, 3, 5 and 7. Mouse lungs were collected on Day 8 for
histopathological analyses as we previously published
[31,33]. Briefly, a cannula was inserted in the trachea, and
the lung was instilled with 10% neutral-buffered formalin at
a constant pressure (25 cm H2O). The trachea was ligated,
and the inflated lung was immersed in 10% neutral buffered
formalin for 24 hr before being embedded in paraffin
wax. Paraffin-embedded sections (4–8 μm thickness)
were stained with periodic acid-Schiff ’s reagent (PAS).
The pathological inflammation, GCHM, and mucin
expression from the midsagittal section of the lungs
were evaluated under a light microscope. For immu-
nohistochemistry (IHC) analyses, mouse lung sections
were stained with primary antibodies and visualized
using the VECTASTAIN Elite ABC Kit (Rabbit IgG,
Vector Laboratories, Burlingame, CA, USA #PK-6101)
(for MUC5B) or the Mouse on Mouse (M.O.M.) Elite
Peroxidase Kit (#PK-2200) (for MUC5AC), according to
protocols supplied by the manufacturers. The pathological
inflammation and GCHM in a midsagittal section from
the lung were evaluated under light microscope. A blinded
pathologist in the Department of Pathobiology, University
of Illinois at Urbana-Champaign (UIUC) independently
examined the tissue sections. Animal studies were carried
out in strict accordance to the protocol approved by the
Institutional Animal Care and Use Committee (Protocol #
11158) at the UIUC.
Statistical analysis
Parametric data were analyzed for statistical significance
by Student’s t-tests, with differences between means con-
sidered significant when p-value <·0.05.
Results
PCN causes ROS/RNS stress in NCI-H292 cells
PCN damages airway epithelial cells by causing oxidative
stress through the release of ROS (Figure 1A). Because
H2O2 and O2
- are capable of interacting with NO within
airways to produce the highly toxic peroxynitrite, we
evaluated the production of total ROS/RNS in NCI-
H292 cells following 24 hr exposure to different concen-
trations of PCN. PCN caused a dose dependent increase
of ROS/RNS (Figure 1B). For example, at 3.125 μg/ml,
PCN only caused a slight increase in ROS/RNS. How-
ever, at clinically relevant concentrations of 6.25 and
12.5 μg/ml, PCN significantly increased the production
of ROS/RNS by 47 and 50%, respectively. We also
examined whether GSH could attenuate the ROS/RNS
production. GSH is a ubiquitous, essential tripeptide (L-
g-glutamyl-L-cysteinyl-glycine) antioxidant containing a
sulfhydryl group that enables it to protect against oxidant-
induced lung injury and inflammation [41]. Importantly,
pretreatment of NCI-H292 cells for 60 min with the anti-
oxidant GSH (≥ 1 mM) before the exposure to PCN
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These results suggest that ROS/RNS induced by PCN may
impair the function of various host proteins in the airway
epithelial cells. However, GSH efficiently neutralizes PCN
toxicity.
PCN induces posttranslational modifications and
degradation of FOXA2
FOXA2 is required for maintenance of normal differen-
tiation of the airway epithelium [32]. Inhibition of
FOXA2 by pro-GCHM Stat6 and EGFR signaling path-
ways appears to be an important early step in the initi-
ation of GCHM and mucus hypersecretion [32,42,43].
We have previously shown that PCN causes GCHM and
mucus hypersecretion by inhibiting the expression of
FOXA2, primarily through the activation of Stat6 and
EGFR [31,33]. However, because ROS/RNS directly
damage proteins, we examined whether PCN-generatedFigure 2 PCN induces posttranslational modifications and degradatio
lysate of NCI-H292 cells previously exposed to PCN for indicated times and
on Protein A/G Agarose, and analyzed by western blots using specific antib
One typical western blot is shown. Densitometry data represent the mean ±
inhibition of FOXA2 expression by PCN. (E-F) Decreasing levels of FOXA2 is ac
ubiquitination (F).ROS/RNS induced posttranslational modifications of
FOXA2, resulting in its degradation in the NCI-H292
cells. PCN caused a time and concentration-dependent
inhibition of FOXA2 expression (Figure 2A-D). Further-
more, western blotting analyses suggest that FOXA2
in the nuclei of NCI-H292 cells exposed to PCN
undergo nitrosylation and acetylation (Figure 2E) and
ubiquitination (Figure 2F). Ubiquitination of FOXA2
suggests that it was destined for degradation. This is
consistent with the finding that increasing levels of
nitrosylation and ubiquitination is accompanied by
decreasing levels of FOXA2 following treatment with
PCN (Figure 2E, F). Interestingly, we were not able to
detect a significant increase in the level of FOXA2
oxidation, methylation or thiolation (data not shown).
Collectively, these results suggest that PCN-generated
ROS/RNS posttranslationally modify FOXA2, leading
to its ubiquitination and degradation.n of FOXA2. FOXA2 proteins were immunoprecipitated from nuclear
concentrations, using anti-FOXA2 monoclonal antibody immobilized
odies. The experiments were repeated three times with similar results.
SD from all three experiments. (A-D) Time and concentration-dependent
companied by increasing levels of nitrosylation and acetylation (E) and
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ability to bind to the promoter of MUC5B gene
Our experimental evidence indicates that FOXA2 is
posttranslationally modified by ROS/RNS produced by
redox activities of PCN. Modified FOXA2 may lose its
transcriptional repressor activity, leading to GCHM and
derepression of mucin biosynthesis genes. MUC5B,
MUC5AC and MUC2 are major secreted mucins in the
airway mucus [44]. MUC5AC and MUC5B are abnor-
mally augmented in airway disease states, such as chronic
bronchitis, COPD, asthma and CF [44]. However, studies
have shown that MUC5B is the predominant mucin in
the CF and COPD airways [45,46]. We used EMSA to
examine the ability of ROS/RNS-modified FOXA2 to
bind the promoter of the MUC5B gene (Figure 3A)
in the NCI-H292 cells. Because PCN inhibits the ex-
pression and induces degradation of FOXA2, EMSA assays
were performed using equal amounts of FOXA2 proteinFigure 3 Posttranslational modification of FOXA2 by PCN reduces its
(underlined) on the MUC5B promoter. (B) Pre-incubation with anti-FOXA2 a
that the MUC5B-promoter binding is FOXA2-specific. Biotin-labeled probes
immunoprecipitated from NCI-H292 cells in presence of indicated amount
probe (Lane 6). (C) FOXA2 immunoprecipitated from PCN-exposed NCI-H2
Biotin-labeled probes were incubated alone (Lane 1) or with equal amount
the absence (Lanes 2, 4 and 6) or in the presence of a 20-fold excess of unimmunoprecipitated from control and PCN-exposed NCI-
H292 cells. Immunoprecipitated FOXA2 proteins free of
antibody were allowed to complex with biotin-labeled DNA
oligos alone or in the presence of excess non-biotin-labeled
competitor. The specificity of the FOXA2 binding to
the promoter of MUC5B was confirmed by a compe-
tition assay with unlabeled probe and with antibodies
against FOXA2 (Figure 3B). FOXA2-DNA complex for-
mation was inhibited by 20-fold excess of competitor
probe (Figure 3B, Lane 6; Figure 3C, Lanes 3, 5, 7), and
by increasing the amounts of anti-FOXA2 antibody
(Figure 3B, Lanes 2, 3, 4, 5). As shown in Figure 3C,
FOXA2–DNA interaction was observed when the FOXA2
extracts were incubated with biotin-labeled probes (Lanes
2, 4 and 6). However, decreasing amounts of FOXA2-DNA
complexes were detected when FOXA2 was immuno-
precipitated from NCI-H292 cells exposed to 1.6 μg/ml
PCN and 6.25 μg/ml PCN treatment (Lanes 4 and 6)binding to the promoter of MUC5B gene. (A) FOXA2 binding site
ntibody blocks the binding of FOXA2 to MUC5B promoter, suggesting
were incubated alone (Lane 1), or with equal amounts of FOXA2
of anti-FOXA2 antibody (Lanes 2–5) or a 20-fold excess of unlabeled
92 cells has reduced ability to bind to the promoter of MUC5B gene.
s of FOXA2 immunoprecipitated from PCN exposed NCI-H292 cells in
labeled probe (Lanes 3, 5 and 7).
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sults suggest that PCN-generated ROS/RNS posttrans-
lationally modify FOXA2, impairing its ability to effectively
bind to the promoter of the MUC5B gene.
PCN induces MUC5AC and MUC5B expression
As shown above, FOXA2 protein extracted from NCI-
H292 cells previously exposed to PCN has posttransla-
tional modifications and impaired binding to the promoter
of the MUC5B gene. These observations suggest that
posttranslationally modified FOXA2 may have reduced
ability to repress the expression of mucin genes. We inves-
tigated the derepression of the transcription of MUC5B
andMUC5AC genes, as well as the biosynthesis and secre-
tion these mucins in lung epithelial cells after treatment
with PCN, by qRT-PCR, western blotting, ELISA and im-
munofluorescence. Previously, we have shown that PCN
significantly induced MUC5B expression in human pri-
mary bronchial epithelial (NHBE) cells and in 16HBE cellsFigure 4 PCN induces the expression of mucins in NCI-H292 and 16H
PCN at indicated concentrations for 24 hr. (A-B) qRT-PCR of MUC5AC and M
densitometry analyses of the expression of both MUC5AC (C-D) and MUC5
antibody against β-actin for loading controls. (G-H) Expression of MUC5AC
exposure to clinically relevant concentrations of PCN, and quantified by EL
in three independent experiments. The western blotting experiments were
densitometry of western blots represent the mean ± SD from all three exp
control cells exposed to same volume of sterile water.cultured at the air-liquid interface [33]. In the presence
of 12.5 μg/ml of PCN, qRT-PCR analyses revealed
that the expression of MUC5AC and MUC5B genes were
increased significantly by 11 and 21-fold, respectively
(Figure 4A-B). Densitometry analyses of western blots
indicate that the expression of MUC5AC and MUC5B pro-
teins increased by 4 and 5-fold, respectively (Figure 4C-F).
These results were confirmed by ELISA analyses, which
showed dose-dependent induction of both MUC5AC and
MUC5B mucins by PCN in both NCI-H292 and 16HBE
cells (Figure 4G-H). It is also apparent that MUC5B was
expressed in higher concentrations both in the presence
and absence of PCN, but the level of induction by PCN
was similar between the two mucins (compared Figure 4G
to 4H). Immunofluorescence staining indicated that, simi-
lar to MUC5B [33], PCN induced the expression of
MUC5AC (green fluorescence) in NHBE (Figure 5A-B)
and 16HBE (Figure 5C-D) cells cultured at the air-liquid
interface to similar extent as the positive control IL-13.BE airways epithelial cells. (A-D) NCI-H292 cells were exposed to
UC5B genes in the presence of PCN. (C-F) Western blotting and
B (E-F). The same membranes were stripped and probed with
(G) and MUC5B (H) mucins in NCI-H292 and 16HBE cells after 24 hr of
ISA. The qRT-PCR and ELISA experiments were performed in triplicates
repeated three times with similar results. Data for qRT-PCR, ELISA and
eriments. *p < 0.05 when PCN-exposed cells were compared with the
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induce the goblet cell hyperplasia and metaplasia in
mouse airways
We have previously shown that chronic exposure to
PCN induces GCHM and mucus hypersecretion [31,33].
However, no studies thus far have comparatively exam-
ined the induction of GCHM and mucus secretion by
wild-type PA versus PCN-deficient mutant. C57BL6
mice were repeatedly challenged with 1 × 106 of wild-
type PA PAO1 or the isogenic PCN-deficient ΔphzS
mutant on Day 1, 3, 5 and 7. All eight mice challenged
with the wild-type PAO1 developed robust GCHM and
mucus hypersecretion as indicated by PAS-stained mucins
(Figure 6A-C, arrows). In contrast, only one out of eight
mice infected with the ΔphzS mutant showed low levels of
isolated mucin-expressing goblet cells (Figure 6A). IHC
analyses indicate that the expression of MUC5AC
(Figure 6B) and MUC5B (Figure 6C) mucin were sig-
nificantly higher in PAO1-infected airways when com-
pared to the ΔphzS infected airways. These results concur
with the results from in vitro studies in NCI-H292 and
16HBE cells, and ex vivo studies using NHBE cells, which
indicate that PCN is a strong inducer of GCHM and
mucus hypersecretion in airways.
GSH alleviates the RNS-mediated FOXA2 modification and
degradation
Next, we examined whether the antioxidant GSH could
attenuate the toxicity of PCN-generated ROS/RNS. WeFigure 5 PCN induces the expression of mucins in polarized NHBE an
expression in polarized NHBE (A) and 16HBE (C) cells cultured at the air-liq
(1 μg/ml) or sterile water (12.5 μl/ml) were used as positive or negative con
(B) and IL-13 (D) was quantified by the ratio of MUC5AC fluorescence sign
nuclei (blue) using the AxioVision Rel. 4.8 software.postulated that GSH could relieve the suppression and
reduce nitrosylation of FOXA2 in the NCI-H292 cells.
As shown in Figure 7A, PCN (6.25 μg/ml) reduced the
expression of FOXA2 by 43%. However, GSH restored
the expression of FOXA2 in a concentration dependent
manner. At concentrations of ≥ 1 mM, GSH increased
the expression of FOXA2 in PCN-exposed NCI-H292
cells above untreated control (Figure 7A-B). In addition,
GSH also reduced the posttranslational modification of
FOXA2. The levels of nitrosylated FOXA2 decreased sig-
nificantly by 40% and 76% in the presence of 0.4 mM
and 1 mM GSH, respectively (Figure 7C-D). Collectively,
these results suggest that higher levels of antioxidants in
airway epithelial cells can reduce posttranslational modifi-
cation and inactivation of FOXA2-mediated by PCN-
generated ROS/RNS. Furthermore, antioxidant treatment
may enhance the expression of FOXA2.
GSH treatment relieves the suppression of FOXA2 and
represses mucin production induced by PCN
Because the epithelial cells treated with GSH overcome
the repression of FOXA2 expression and reduce post-
translational modification by PCN, we postulated that
restored FOXA2 in turn, could inhibit the expression of
MUC5AC and MUC5B mucins in the NCI-H292 cells.
Western blot analyses showed that in the absence of GSH,
PCN (12.5 μg/ml) reduced the expression of FOXA2 by
50%, with corresponding 5-fold increase in MUC5AC and
MUC5B expression (Figure 8A-D). Addition of GSHd 16HBE airways epithelial cells. (A-D) Induction of MUC5AC mucin
uid interface by PCN (12.5 μg/ml). Epithelial cells exposed to IL-13
trol for MUC5AC induction, respectively. MUC5AC induction by PCN
al (green) divided by the total fluorescence signal of DAPI stained
Figure 6 PCN-deficient mutant has reduced ability to induce the goblet cell hyperplasia in mouse airways. C57BL6 mice (n = 8) were
repeatedly challenged with 1 x 106 of wild-type PA PAO1 or the isogenic ΔphzS mutant on Day 1, 3, 5 and 7. Mouse lungs were harvested, fixed
and paraffin-embedded for PAS staining and for IHC. (A) PAS staining and quantification of goblet cells after infection by PAO1 versus ΔphzS.
(B) IHC and quantification of MUC5AC induction by PAO1 versus ΔphzS. (C) IHC and quantification of MUC5B induction by PAO1 versus ΔphzS
mutant. PAS, MUC5AC and MUC5B-positive cells were quantified using the AxioVision Rel. 4.8 software. Five representative microscopic fields at
10x magnification from each mouse were quantified. Data represent the mean ± SD from all eight mice.
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responding decrease in the expression of MUC5AC and
MUC5B mucins (Figure 8A, C-D). Restored expression of
FoxA2 is also associated with repression of MUC5AC and
MUC5B transcription (Figure 8E-F). Collectively, these
results suggest that GSH effectively neutralizes PCN
toxicity, restoring FOXA2 function, which in turn, may re-
press the transcription of MUC5AC and MUC5B genes as
well as the expression of both mucins in airway epithelial
cells.
Discussion
PCN is a redox-active virulence factor of PA. We have pre-
viously shown that PCN inhibits the expression of FOXA2
through the activation of pro-GCHM signaling pathway
Stat6 and EGFR [33]. In this study, we demonstrate
PCN-generated ROS/RNS causes posttranslational modifi-
cations–nitrosylation, acetylation, and ubiquitination–ofFOXA2, resulting in degradation of the transcriptional
repressor of GCHM. Furthermore, FOXA2 modified by
PCN-generated ROS/RNS has reduced binding capacity to
the promoter of the MUC5B gene. The loss of FOXA2 ex-
pression is positively correlated to derepression ofMUC5AC
and MUC5B transcripts, as well as the overexpression of
both mucins. Importantly, the antioxidant GSH neutralizes
PCN-mediated toxicity and reduces the nitrosylation and
suppression of FOXA2 by PCN-generated ROS/RNS. Res-
toration of FOXA2 expression is positively correlated to the
repression of both MUC5AC and MUC5B genes and mu-
cins. Collectively, these results suggest that posttranslational
modification and inactivation of FOXA2 induced by PCN-
generated ROS/RNS may also contribute to GCHM and
mucus hypersecretion.
There has been a continual debate as to the import-
ance of PCN to the pathogenesis of diseases in human
airways, especially in CF. This is primarily because of
Figure 7 GSH attenuates the repression and nitrosylation of FOXA2 by PCN. (A-B) GSH treatment overcomes PCN-mediated inhibition of
FOXA2 expression. NCI-H292 cells were pretreated with various concentrations of GSH for 60 min before exposure to PCN (6.25 μg/ml). Nuclear
proteins were harvested for Western blot using anti-FOXA2 (A) and quantified with densitometry (B). The same membrane was stripped and
probed with antibody nuclear protein Histone H3 for loading control. (C-D) GSH reduces nitrosylation of FOXA2 by PCN. NCI-H292 cells were
pretreated with PBS (negative control) or with GSH for 60 min before exposing to PCN. FOXA2 was immunoprecipitated from nuclear extracts,
and equal amounts were loaded for western blot analyses using anti-FOXA2 and anti-nitrotyrosine antibodies, respectively (C). FOXA2
nitrosylation was quantified by densitometry (D). The experiments were independently performed three times with similar results. Western blots
from one typical experiment are shown. Densitometry data represent the mean ± SD from all three experiments. *p < 0.05 when comparing
GSH-pretreated cells against cells exposed only to PCN.
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limited number of sputum samples from CF and non-CF
bronchiectatic patients [12]. In some of the samples,
PCN levels as high as 27 and 16.5 μg/ml were recovered,
the latter of which, was from a CF patient. However, a
few other samples showed either low or non-detectable
levels of PCN. Thus, a new study involving a larger co-
hort of patients is needed. In addition, one recent study
has shown that some PCN-deficient CF isolates of PA
are associated with BPI-ANCA and progressive lung dis-
ease, suggesting that toxin-mediated alterations are not
important for infection in this subpopulation of CF pa-
tients [47]. However, it is important to note that most of
the CF clinical isolates of PA secrete more PCN in vitro
[31]. Furthermore, PCN is overproduced by laboratory
strains grown in minimal medium supplemented with
CF sputum rather than glucose [13]. In addition, over-
production of PCN has been reported among the
hypervirulent Liverpool Epidemic CF strains of PA [48].
More importantly, PCN hypersecretion was correlated
with episodes of pulmonary exacerbations in a set of CF
patients [49]. We have previously shown that PCN is im-
portant for acute and chronic infection of mouse airways[30,31]. Additional evidence of the importance of PCN
during PA infection include both in vitro and in vivo
models of infection or intoxication, and the induction of
GCHM and mucus hypersecretion [31,33]. The results
from our current study provide additional supporting
evidence of the involvement of PCN in both induction
and exacerbation of GCHM and mucus hypersecretion
in CF and non-CF bronchiectatic and COPD airways
chronically infected by PA strains producing PCN.
Apart from PCN, other virulence factors of PA, includ-
ing LPS are known to induce oxidative stress [50]. How-
ever, as we discussed earlier, the O-antigen of PA LPS is
frequently mutated [7]. In addition, ~40% of PA isolates
are non-flagellated, especially in mucoid isolates that
reside in the chronic CF airways [6]. Comparative stud-
ies between the wild-type PA strain PAO1 and its iso-
genic ΔphzS mutant indicate that inability to synthesize
PCN hampers the ability of PA to induce GCHM and
mucus hypersecretion. Thus, PCN appears to be an im-
portant inducer of ROS/RNS, which contributes to
mucus hypersecretion in diseased airways chronically
infected by PA. This argument is supported by studies
showing that ROS/RNS play a prominent role in the
Figure 8 Restoration of FOXA2 expression by GSH attenuates PCN-mediated overexpression of MUC5AC and MUC5B mucins.
(A-D) GSH treatment restores the expression of FOXA2 and attenuates the expression of MUC5AC and MUC5B mucins. NCI-H292 cells with or
without GSH pretreatment were exposed to PCN (12.5 μg/ml) or sterile water (control) for 24 hr. Nuclear proteins were harvested for Western
blots using anti-FOXA2 whereas total protein was probed with anti-MUC5AC or MUC5B antibodies (A) and quantified with densitometry
(B-D). The same membranes were stripped and probed with antibody nuclear protein Histone H3 for loading control for FOXA2 and β-actin as
loading control for MUC5AC and MUC5B. The experiments were independently repeated three times. Densitometry data represent the mean ±
SD from three experiments. *p < 0.05 when comparing GSH-pretreated cells against cells exposed only to PCN. (E-F) GSH represses PCN-mediated
induction of MUC5AC and MUC5B gene expression. The expression of mucin genes was analyzed by qRT-PCR. The experiments were performed
in triplicates in three independent experiments. The data represent the mean ± SD from three experiments.
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disease, CF, COPD and asthma [51-54], including the re-
cent clinical data suggesting that oxidative damage of
pulmonary proteins during chronic infection may con-
tribute to the decline of lung function in CF patients
[52]. These clinical findings are consistent with the
FOXA2 inactivation by PCN-generated ROS/RNS, which
may contribute and exacerbate GCHM and mucus
hypersecretion in diseased airways colonized by PA.
Previously, we have demonstrated that PCN can in-
hibit the expression of FOXA2 through the activation of
IL-4/IL-13/Stat6 and EGFR signaling pathways [33]. Es-
pecially relevant is the finding that EGFR, a major pro-
GCHM pathway, is inducible by ROS [55], includingthose generated by PCN [33,56]. Thus, PCN-mediated
GCHM and mucus hypersecretion in diseased airways
chronically colonized by PA is likely a cumulative effect
of ROS/RNS-mediated posttranslational modification of
FOXA2 and the activation of IL-4/IL-13-STAT6 and
EGFR signaling pathways that inhibit the expression of
FOXA2. However, excessive levels of PCN-generated
ROS/RNS may potentially impair the function of com-
ponents of Stat6 and EGFR pathways. Thus, it is likely
that PCN-mediated repression of FOXA2 is a bigger
contributor of GCHM and mucus hypersecretion than
the partial loss of function for both Stat6 and EGFR sig-
naling components. Future studies will address these
matters in more detail.
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important roles in pulmonary diseases [41]. One study
in rats has shown that the concentration of lung GSH is
approximately 2 mM [39]. GSH at concentrations as
high as 10 mM has been used in cell culture experi-
ments [40]. Importantly, inhaled GSH therapy has been
shown to improve the lung function of CF patients, as
well as liquefy the mucus [57-59]. Our results provide a
possible mechanistic basis for the beneficial treatment
with thiols. For example, GSH at physiologically relevant
concentrations of 0.4 – 2.5 mM not only reduces the
production of PCN-generated ROS/RNS, it also attenu-
ates the posttranslational modifications and inactivation
of FOXA2, and, in the process, suppresses the produc-
tion of excessive mucins. Collectively, our experimental
results suggest that providing physiologically relevant con-
centrations of GSH can counter the induction of GCHM
by clinically relevant concentrations of PCN (≤ 25 μg/ml).
Future studies will examine the efficacy of GSH against
GCHM and mucus hypersecretion mediated by PCN in
mouse airways, as well as during infection by wild-type
versus PCN-deficient laboratory and clinical strains of PA.
One surprising finding from our studies is the robust
mucin secretion induced by PCN in the polarized NHBE
cells. At a clinically relevant concentration of 12.5 μg/
ml, PCN induces higher levels of MUC5AC expression
than IL-13 (1 μg/ml) after 24 hr of exposure in NHBE
cells. Similarly, PCN also induces substantial expression
of MUC5B mucin in the polarized NHBE cells [33].
Interestingly, induction of mucin secretion with short
exposure to IL-13 has not been reported. One potential
discrepancy between the current study and other reports
lies in the IL-13 concentration used. We exposed NHBE
cells to 1 μg/ml of recombinant human IL-13 and probed
for mucin expression at 24 hr [31,33] whereas other stud-
ies used 10 ng/ml over 7–14 days to induce differentiation
of mucous cells and increases in MUC5AC protein
[60-62]. However, there have been other short duration
studies that used higher concentrations of IL-13 to induce
GCHM and mucin expression. For example, instillation of
mouse recombinant IL-13 (250 ng per/mouse, twice over
48 hr; or 500 ng/mouse, once in 24 hr) has been shown to
induce GCHM and mucin overexpression within mouse
airways [63,64]. Thus, our current study resembles the
studies that used higher amounts of IL-13 in short dur-
ation of exposure.
We acknowledge limitations to the interpretation of
the results derived from the current study. Even though
we have combined various techniques, including ELISA,
immunohistochemistry, immunofluorescence, western blot
and qRT-PCR to examine the impact of PCN on the ex-
pression of FoxA2 and mucin genes, a large portion of the
data is based on in vitro analyses in immortalized cell lines.
In addition, densitometry analysis of western blot is semi-quantitative and has limited sensitivity. Another limita-
tion is on the mechanistic aspects of this study. We have
shown that PCN-mediated posttranslational modifications
of FOXA2 is positively associated with GCHM and up-
regulation of MUC5AC and MUC5B genes and mucins.
Directly demonstrating that these posttranslational modi-
fications of FOXA2 inactivate its function and cause
GCHM and mucin hypersecretion remain unproven, and
difficult. Additional experiments to unravel the mecha-
nisms by which PCN-generated ROS/RNS posttransla-
tionally modify and inactivate FOXA2 may include the
use of mass spectrometry to map the amino acid residues
modifies by ROS/RNS. This will be followed by site-
directed mutagenesis and constructing various versions of
mutated FOXA2 recombinants, and studying the resis-
tance or susceptibility of these genetically altered FOXA2
recombinants to ROS/RNS-mediated posttranslational
modifications and mucin gene regulation in both airway
epithelial cells and in mouse lungs.
In summary, the present study shows that PCN down-
regulates the expression of FOXA2 through posttransla-
tional modifications mediated by ROS/RNS. Modified
FOXA2 is degraded, as well as having reduced ability to
bind the promoter of MUC5B gene. The degradation
and functional impairment of FOXA2 is positively corre-
lated to elevation of GCHM and mucin biosynthesis.
Thus, inhibition of PCN biosynthesis and neutralization
of its toxicity, and maintenance of FOXA2 function in
diseased airways chronically infected by PA may be
therapeutically useful to improve the lung functions of
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